68 weeks (aggressive) 9-12 x 10 mg vials Maintenance at 12 mg weekly
What side effects were observed in clinical trials
Kim YS, Joo WS, Jin BK, Cho YH, Baik HH, Park CW
In its meeting notice, the FDA listed these as the uses evaluated: BPC-157: ulcerative colitis TB-500: wound healing KPV: wound healing and inflammatory conditions Emideltide: opioid withdrawal, chronic insomnia, and narcolepsy Semax: cerebral ischemia, migraine, and trigeminal neuralgia Epitalon: insomnia MOTS-c: obesity and osteoporosis Pinchas Cohen, MD, who discovered MOTS-c, said it hasnt been studied for osteoporosis, but there were some bone density findings in mice
The fat-burning substances include inositol, which helps the liver remove fat